Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study

Abstract Background Efficacy of second-line treatments after first-line platinum-based chemotherapy in advanced cervical cancer is modest. This open-label, single-arm, multicentre, proof-of-concept phase 2 study evaluated fruquintinib plus sintilimab in advanced cervical cancer. Methods Patients rec...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Xiaohua Wu, Danbo Wang, Jing Wang, Yi Huang, Tienan Yi, Guiling Li, Jieqing Zhang, Keming Wang, Yu Kang, Anwen Liu, Xiaotian Han, Xuemei Ren, Li Li, Runfeng Yang, Quan Li, Qing Yang, Bingbing Zhao, Juan Wang, Hanjie Yi, Yue Tan, Keyan Chen, Puhan Lu, Haiyan Shi, Panfeng Tan, Songhua Fan, Michael M. Shi, Weiguo Su
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Nature Portfolio 2026-04-01
Serie:	Communications Medicine
Länkar:	https://doi.org/10.1038/s43856-026-01572-z
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!